Leukemia transplant study tests lower radiation for better outcomes
NCT ID NCT06803745
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests whether a lower dose of total body irradiation (200 cGy) before a bone marrow transplant works as well as a standard higher dose (400 cGy) for people with acute leukemia. The goal is to see which dose leads to fewer severe side effects like graft-versus-host disease and better survival without relapse. About 160 participants will be randomly assigned to one of the two radiation doses as part of their transplant preparation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
total body irradiation (TBI) at 200 or 400 cGy
What this could lead to
If it works, this could identify the best radiation dose to reduce severe complications and improve long-term survival after transplant for leukemia patients.
What could go wrong
This is a phase 2 trial with only 160 participants, so results may not apply to everyone. Radiation can cause side effects, and the lower dose might not control the disease as well.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••